Skip to content
Versanis
  • Science
    • Our Approach
    • Areas of Focus
      • Obesity
      • Heart Failure in Obesity
    • Pipeline
    • Scientific Publications
  • About Us
    • Our Focus
    • Leadership Team
    • Board of Directors
  • News
  • Careers
  • Contact

Long-term safety and tolerability of bimagrumab (BYM338) in sporadic inclusion body myositis

© 2023 Versanis Bio

  • Privacy Policy
  • Terms of Use